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Abstract
Background: Triple-negative breast cancer (TNBC) has a high risk of relapse and there are few chemotherapy
options. Although 5-hydroxytryptamine (5-HT, serotonin) signaling pathways have been suggested as potential
targets for anti-cancer drug development, the mechanism responsible for the action of 5-HT in TNBC
remains unknown.
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to measure
mRNA and protein levels, respectively. Cell proliferation was measured using CellTiter 96 Aqueous One Solution. siRNA
transfection was used to assess involvement of genes in cancer invasion, which were identified by Matrigel transwell
invasion assay. Levels of 5-HT and vascular endothelial growth factor (VEGF) were measured using ELISA kits. Chick
chorioallantoic membrane (CAM) assay and mouse tumor model were used to investigate the in vivo effects of
SB269970, a 5-HT7 receptor antagonist, and BJ-1113, a novel synthetic compound.
Results: TNBC cell lines (MDA-MB-231, HCC-1395, and Hs578T) expressed higher levels of tryptophan hydroxylase
1 (TPH1) than hormone-responsive breast cancer cell lines (MCF-7 and T47D). In MDA-MB-231 cells, 5-HT promoted
invasion and proliferation via 5-HT7 receptor, and interestingly, the stimulatory effect of 5-HT on MDA-MB-231 cell
invasion was stronger than its effect on proliferation. Likewise, downstream signaling pathways of 5-HT7 differed
during invasion and proliferation, that is, Gα-activated cAMP and Gβγ-activated kinase signaling during invasion, and
Gβγ-activated PI3K/Akt signaling during proliferation. Also, 5-HT increased the protein expressions of TPH1 and VEGF
in MDA-MB-231 cells. These results provide insight of the stimulatory effect of 5-HT on breast cancer progression;
5-HT was found to act more strongly during the first stage of metastasis (during invasion and migration) than during
the later proliferative phase after local invasion. Interestingly, these actions of 5-HT were inhibited by BJ-1113, a
6-amino-2,4,5-trimethylpyridin-3-ol analog. BJ-1113 blocked intracellular signaling pathways initiated by 5-HT7
receptor activation, and exhibited anti-proliferative and anti-invasive activities against MDA-MB-231 cells. Furthermore,
the inhibitory effect of BJ-1113 against MDA-MB-231 tumor growth was greater than that of SB269970, a 5-HT7
receptor antagonist.
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Conclusions: 5-HT7 receptor which mediates 5-HT-induced cancer progression is a potential therapeutic target in
TNBC, and BJ-1113 offers a novel scaffold for the development of anti-cancer agents against TNBC.
Keywords: Triple negative breast cancer, Autocrine 5-HT action, Tryptophan hydroxylase 1, 5-HT7 receptor,
6-Amino-2,4,5-trimethylpyridin-3-ol
Background
Breast cancer is the most common cancer in women and
the second leading cause of cancer death in women [1].
Treatment typically involves combinations of surgery,
radiation therapy, and chemotherapy. Chemotherapeutic
options for breast cancers depend on the expressions of es-
trogen receptor (ER) and progesterone receptor (PR), and
on the amplification of human epidermal growth factor re-
ceptor 2 (HER-2/Neu) [2]. Triple-negative breast cancer
(TNBC) does not express ER, PR, or HER-2/Neu, and is a
highly aggressive subtype of breast cancer. Although TNBC
is highly susceptible to chemotherapy (e.g., platinum-based
agents), the risk of relapse is high because the presence of
residual cancer cells is common after treatment [3–5], and
these cells tend to exhibit an increased capacity for prolifer-
ation, invasion, and metastasis [6–8]. Furthermore, patients
with recurrent TNBC after standard chemotherapeutic reg-
imens have limited chemotherapeutic options [9]. Accord-
ingly, novel molecular targets and agents for such targets
are needed to treat TNBC.
A recent study demonstrated 5-HT (5-hydroxytryptamine,
serotonin) production in patients with breast cancer [10],
which suggests components of the 5-HT signaling path-
way may offer potential drug targets. 5-HT is a neuro-
transmitter produced in brain. It is also produced by
enterochromaffin cells in gut, which accounts for ~95% of
5-HT production, and epithelial cells in mammary glands.
5-HT is involved in multiple biological functions, such as,
immune system [11], gut physiology [12], and epithelial
homeostasis of various organs, such as, mammary glands,
lungs, pancreas, liver, and prostate [13–17]. In the
mammary gland, 5-HT produced by the prolactin-induced
expression of the 5-HT biosynthesis gene tryptophan hy-
droxylase 1 (TPH1) [13] induces lactation-to-involution
switching via 5-HT7 receptor-dependent tight junction
disruption [18, 19]. Interestingly, whereas 5-HT has a
growth inhibitory effect on normal mammary epithelial
cells, it stimulates the proliferation of breast cancer cells
at sub-micromolar concentrations [20]. 5-HT also stimu-
lates angiogenesis, which involves the proliferation, inva-
sion, and migration of endothelial cells [21–25]. Although
the mechanisms responsible for the effects of 5-HT on the
malignant phenotype of breast cancer remain unclear, the
angiogenesis-promoting effect of 5-HT suggests that it
may stimulate cancer cell proliferation and invasion, the
required processes of cancer progression [26–28]. In
addition, the signaling pathway associated with angiogenic
action of 5-HT is known to be mediated by a mechanism
similar to that associated with the angiogenic effect of
vascular endothelial growth factor (VEGF) (e.g., via the
activation of PI3K/Akt signaling) [29], which suggests
potential overlap between signaling molecules with re-
spect to cancer proliferation/invasion and angiogenesis.
In the present study, we investigated the role and
mode of action of 5-HT in breast cancer progression.
In addition, based on our previous results that 6-
amino-2,4,5-trimethylpyridin-3-ol analogues inhibit VEGF-
induced angiogenesis [30], and that one of the derivatives
also blocked angiogenic 5-HT signaling in endothelial cells
[31], we examined the therapeutic potential of BJ-1113,
one of the aminopyridinol derivatives, which showed
greatest antiangiogenic activity, by comparing its abilities
to antagonize 5-HT7 receptor (SB269970) and to inhibit
PI3K/Akt, a common signaling molecule downstream of
5-HT7 and VEGF receptors.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and
RPMI1640 were purchased from Hyclone. Cortisone acet-
ate and VEGF were from R&D Systems (Minneapolis, MN,
USA). Fetal bovine serum (FBS), penicillin, and strepto-
mycin were obtained from Gibco (Grand Island, NY, USA).
Cholera toxin, 2′,2′-dideoxyadenosine (DDA), Forskolin,
Pertussis toxin, LY390762, and sodium pyruvate were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
AZM-475271, Gallein, Cyanopindolol hemifumarate,
Cinanserin hydrochloride, and SB-269970 hydrochloride
were purchased from Tocris Bioscience (Tocris House,
Bristol, UK). Wortmannin was from Biomol (Plymouth
Meeting, PA, USA). Antibodies directed against phospho-
p85-PI3K (at Tyr488), p85-PI3K, phospho-AKT (at T308),
AKT, phospho-mTOR (at Ser2448), mTOR, phospho-ERK,
ERK, phospho-p38, p38, VEGF were purchased from Cell
Signaling Technology Inc. (Beverly, MA, USA), and
β-Actin antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Tryptophan
hydroxylase 1 and MMP-9 antibodies were obtained from
Abcam (Cambridge, MA, USA). Antibodies against
5-HT1D and 5-HT7 receptors were purchased from
Novus Biologicals (Littleton, CO, USA). BJ-1113 was
synthesized as described previously [30]; its chemical
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structure is shown in Fig. 5a. Cisplatin purchased from
Shandong Boyuan Pharmaceutical Co. Ltd. (Shandong,
China) was dissolved in dimethylsulfoxide (DMSO) to
make stock solution and diluted 100 × with 1× Phosphate
Buffered Saline (PBS) for in vivo experiments.
Cell lines and 5-HT treatment
The MCF-10A human breast cell and HCC-1395, T47D,
and Hs578T human breast cancer cell lines were pur-
chased from the Korean Cell Line Bank, Seoul. MCF-7
and MDA-MB-231 human breast cancer cells were ob-
tained from the American Type Culture Collection
(Manassas, VA, USA). Hs578T, MCF-7 and MDA-MB-231
were grown in DMEM supplemented with 10% FBS and
1% penicillin/streptomycin, whereas T47D, HCC-1395 and
MCF-10A were maintained in RPMI1640 supplemented
with 10% FBS and 1% penicillin/streptomycin. To measure
tumor growth by bioluminescent imaging, MDA-MB-231
cells were retrovirally transduced to express both effluc
and Thy1.1. Thy1.1-positive cells were sorted using
CD90.1 MicroBeads (Miltenyi Biotec, Auburn, CA, USA).
Established stable cells expressing effluc and Thy1.1 are
herein referred to as MDA-MB-231/effluc cells and were
used to generate tumor-bearing mice.
Proliferation assay
Cell proliferation was determined using CellTiter 96
Aqueous One Solution (Promega Corporation, WI,
USA) according to the manufacturer’s instructions.
Cells were seeded in 96-well plates at a density of
2.5 × 104 cells/cm2, and on the following day were serum
starved overnight in media containing 0.2% FBS. They
were then pre-treated with indicated concentration of
drugs for 1 h prior to being treated or not with 5-HT or
serum. After 72-h of incubation, CellTiter 96 Aqueous
One Solution was added and cells were incubated for a
further 2 h. Color intensities were measured using micro-
plate reader (Versamax, Molecular Devices, Inc., USA) at
490 nm.
siRNA transfection
MDA-MB-231 cells plated in 96-well plates (proliferation
assay) or 6-well plates (transfection efficiency meas-
urement) were transfected with two different sequences
of siRNAs targeting TPH1, 5-HT1D, or 5-HT7 (Bioneer
Corporation, CA, USA) using Dharmacon reagent
(Thermo Scientific, MA, USA) when 50% confluent. They
were then incubated with transfection mixture consisting
of 100 nM siRNA and Dharmafect 1 for 24 h and then
with regular media for another 6 h. Cells transfected with
TPH1 were used for cell proliferation assays or for VEGF
secretion measurements.
Polymerase chain reaction (PCR)
Total RNA was extracted using Trizol reagent (Invitrogen
Corporation, CA, USA) according to the manufacturer’s
protocol. cDNA was synthesized using the Goscript reverse
transcription system (Promega Corporation, WI, USA).
Quantitative mRNA analysis was performed using a
QuantiTect SYBR Green PCR kit (Qiagen, CA, USA).
The primer sequences used were; 5-HTR1D (sense
5′-TACTGGGCAATCACAGATGC-3′ and antisense 5′-
TGGAGATGCAGATGGAGATG-3′) and 5-HTR7 (sense
5′-ACTCTACCGCAGTGGCATTT-3′ and antisense 5′-
TGTGTTTGGCAGCACTCTTC-3′). Primers for GAPDH
were supplied by Qiagen, CA, USA. RT-PCR was per-
formed in 0.2-mL tubes containing 10× Taq buffer, dNTP,
Taq DNA polymerase (Takara, Japan), and 25 pmole of
TPH1 primer (forward 5′-ATGATTGAAGACAATAAG
GAG-3′ reverse 5′-AAGTTTTTGAGATACTCTCTG-3′)
or GAPDH primer (forward 5′-GGTGAAGGTCGGAGT
CAACG-3′ and reverse 5′-CAAAGTTGTCATGGATG
ACC-3′). Amplified PCR products were separated in 1.5%
agarose gels, visualized using a gel imaging system (UVP,
Cambridge, UK), and quantitated by measuring band
densities.
Determination of VEGF and 5-HT levels
To determine VEGF and 5-HT levels in cells and chick
chorioallantoic membrane (CAM) tumor tissues, ELISA
kits specific to VEGF (R&D Systems Inc., MN, USA) or
5-HT (IBL America, MN, USA) were used. Cells seeded
in 24-well plates at 1 × 105 cells/cm2 were serum-starved
overnight and treated with BJ-1113 or vehicle in the
presence of Hank’s balanced salt solution for 24 h.
The cell culture supernatants were collected and
saved at −80 °C for 5-HT and VEGF content determin-
ation. To determine VEGF and 5-HT contents in CAM
tumors, tissues were homogenized in PBS and centrifuged
at 900 g for 10 min at 4 °C. 5-HT concentrations in cell
culture supernatants and CAM tumor tissues were deter-
mined according to the manufacturer’s instructions.
Protein extraction and western blotting
Whole cell lysates were prepared using radioimmuno-
precipitation assay (RIPA) buffer containing 1× protease
and phosphatase inhibitor cocktail (Thermoscientific,
CA, USA) RIPA buffer was composed of 150 mM
Sodium chloride, 1% Triton X-100, 0.5% Sodium deoxy-
cholate, 0.1% SDS and 50 mM Tris adjusted to pH 8.0.
After lysing cells with RIPA buffer, they were centrifuged
at 16200 g for 15 min and supernatants containing
soluble proteins were collected. Protein contents were
measured using BCA protein assay reagent (Pierce,
Rockford, IL, USA). Equal amounts of total proteins
were then separated by SDS-PAGE and transferred onto
Hybond ECL nitrocellulose membranes (Amersham Life
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Science, Buckinghamshire, UK) at 200 mA for an hour.
Membranes were blocked in 5% skim milk in Tris-buffered
saline (TBS)-Tween 20 (TBS-T) at room temperature for
1 h, incubated in skim milk-TBS overnight at 4 °C, washed
three times with TBS-T, and incubated with horseradish
peroxidase-conjugated secondary antibody in skim milk-
TBS for 1 h at room temperature. Immunoreactive pro-
teins were visualized using an ECL kit (Pierce, Rockford,
IL, USA) and digitally processed using LAS-4000 mini
(Fuji, Japan). Membranes were stripped and reprobed with
an actin antibody as a loading control. Densitometric
analysis of blots was performed with Multi Gauge Ver 3.2
imaging software in a Fuji Image Station.
Invasion assay
Invasion assays were performed as described by Banskota
et al., 2015 [32] with slight modification. Briefly, the inner
and outer surfaces of Transwell inserts (BD Falcon,
Fig. 1 Autocrine action of 5-HT in MDA-MB-231 human breast cancer cell proliferation and its mediation through 5-HT7 receptor. a, b The mRNA
(a) and protein (b) expression levels of TPH1 expression in TNBCs (MDA-MB-231, HCC-1395, and Hs578T) and hormone-responsive breast cancer
cells (MCF-7 and T47D). The bar graph represents relative densities of TPH1 (TPH1 mRNA/GAPDH or TPH1 protein/β-Actin) normalized versus those in
MCF-7 cells. Results are the means of three independent experiments. *P < 0.05 vs. MCF-7 cells. c 5-HT secretion in TNBCs, hormone-responsive breast
cancer cells and MCF-10A human normal breast cells was measured by ELISA. *P< 0.05 vs. MCF-10A cells, #P< 0.05 vs. T47D cells. d Transfection of
MDA-MB-231 cells with TPH1 siRNA suppressed proliferation. The bands underneath the bar graph represent TPH1 mRNA expressions detected by PCR.
*P < 0.05 vs. non-target (NT) siRNA-transfected controls. e Comparison of cell proliferation induced by 5-HT in MDA-MB-231 and MCF-7 human breast
cancer cells. *P < 0.05 vs. vehicle-treated controls. f 5-HT-treated MDA-MB-231 proliferation was examined in the presence of cyanopindolol (CYPD),
LY310762, cinanserin (CISN), or SB269970. *P< 0.05 vs. vehicle-treated controls. #P< 0.05 vs. 5-HT-treated cells. g MDA-MB-231 cell proliferation in the
presence of serum was inhibited by 5-HT7 antagonist. *P < 0.05 vs. vehicle-treated controls. h, i The mRNA expression determined by real time PCR
(h) and protein expression (i) of 5-HT7 receptors in TNBCs (MDA-MB-231, HCC-1395, and Hs 578 T), hormone-responsive breast cancer cells (MCF-7 and
T47D), and MCF-10A normal breast cells. *P< 0.05 vs. T47D cells. j Effect of 5-HT on MCF-10A cell proliferation. k Effect of 5-HT receptor-downstream
signaling inhibitors on 5-HT-stimulated cell proliferation. *P< 0.05 vs. vehicle-treated controls. #P< 0.05 vs. 5-HT-treated cells
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Franklin Lakes, USA) were coated with matrigel and colla-
gen, respectively. Serum or 5-HT was added to the lower
Transwell chamber except the control group. Cell suspen-
sion (100 μl) with or without the indicated inhibitors at in-
dicated concentrations were added to upper Transwell
chambers, and 18 h later, cells were fixed and stained.
Numbers of cells invading per field were captured at
200× magnification using a digital camera fitted to
the microscope.
cAMP Measurements
MDA-MB-231 cells (1 × 105 cells/cm2 in 24 well plate)
pretreated with BJ-1113 in DMEM High Glucose
medium containing 1% FBS and then stimulated with
forskolin, 5-HT, cholera toxin, or pertusis toxin. After
washing cells three times with cold PBS, lysis buffer was
added to each well, and cells were lysed by freezing
(−80 °C for 1 day) and thawing in ice with gentle mixing.
Cells were then centrifuged at 600 × g for 10 min at 4 °C
to remove cellular debris. Supernatants were assayed for
cAMP using a cAMP ELISA kit (R & D Systems Inc.,
MN, USA).
CAM assay
Fertilized eggs were purchased from Siprigol Poultry
Farm (Gyeongsan, Korea) and the CAM was prepared as
described previously [33]. For tumor angiogenesis
experiments, MDA-MB-231 human breast cancer cells
(1.5 × 106 cells/CAM) were inoculated onto the CAM
with or without the indicated concentration of drugs
[34, 35]. Numbers of vessel branch points contained in a
tumor region were counted by two observers in a
double-blind manner. Tumor tissues detached from the
membrane were weighed and then preserved at −80 °C
for 5-HT ELISA and western blotting.
Chick embryo experiments were performed in ac-
cordance with the institutional guidelines of the
Institute of Laboratory Animal Resources (1996) and
Fig. 2 5-HT stimulated MDA-MB-231 cell invasion through 5-HT7 receptors. a MDA-MB-231 cells seeded in a Matrigel-coated transwell inserts were
serum-starved and then treated with 5-HT for 18 h. Serum was used as a positive control to induce invasion. Invading cells were counted in five
different fields per well, and results were averaged. The bar graphs represent the relative numbers of invading cells expressed as the means ± SEMs of
three independent experiments. *P < 0.05 vs. vehicle-treated controls. b Cells were pretreated with LY310762 or SB269970 for 1 h prior to 5-HT (10 μM)
treatment. *P < 0.05 vs. vehicle-treated controls. #P < 0.05 vs. 5-HT-treated cells. c-e MDA-MB-231 cells were transfected with two different sequences
of siRNAs targeting either NT, 5-HT1D, or 5-HT7 receptor. The bar graphs represent mRNA and protein expression levels of TPH1, 5-HT1D, 5-HT7, and
MMP-9, as determined by real time PCR (c) and western blot (d) *P < 0.05 vs. NT siRNA-transfected controls. e 5-HT-induced invasion ability was
measured by invasion assay. *P < 0.05 vs. vehicle-treated controls. #P < 0.05 vs. cells treated with NT siRNA and 5-HT. f Serum-induced invasion was
examined in MDA-MB-231 cells transfected with NT or two different sequences of TPH1 siRNA. *P < 0.05 vs. vehicle-treated controls. #P < 0.05 vs. NT
siRNA-transfected cells
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Yeungnam University for the care and use of labora-
tory animals (2009).
Anti-tumor activity measurements in mouse tumor
models
Six-week-old BALB/c nude mice were purchased from
Orient Co. Ltd., Korea and housed under pathogen-free
conditions under a 12-h light/dark cycle with access to
food pellets and tap water ad libitum. Mice were
injected subcutaneously with 1 × 107 MDA-MB-231-
effluc cells in 200 μl of DMEM/matrigel (1:1) into a
flank. Tumors were measured every two days and vol-
umes were calculated using the formula:
V mm3
  ¼ Length=2  Widthð Þ2
When tumors reached 200 mm3, mice were divided
into different groups and injected intraperitoneally with
drugs once daily. Mice were monitored daily for physical
condition (body weight changes and rustling behavior).
After 19 days of treatment, mice were sacrificed in a
CO2 gas-filled chamber, and the excised tumors were
measured and weighed.
For in vivo bioluminescent imaging (BLI), mice were
administered D-luciferin i.p. injection. After 10 min of
D-luciferin injection, BLI was performed using the IVIS
Lumina III imaging system (PerkinElmer, MA, USA).
Grayscale photographic images and bioluminescent
color images were superimposed using LIVINGIMAGE
(version 2.12, PerkinElmer) and IGOR Image Analysis
FX software (WaveMetrics, Lake Oswego, OR, USA).
BLI signals are expressed as photons per cm2 per second
per steradian (P/cm2/s/sr). All mice were anesthetized
using 1–2% isoflurane gas during imaging.
Mouse experiments were performed according to the
institutional guidelines of the Institute of Laboratory
Animal Resources (1996) and of Yeungnam University
for the care and use of laboratory animals (2009). The
guidelines also contain a protocol for early euthanasia/
humane endpoints for mice that become severely ill
Fig. 3 5-HT-induced MDA-MB-231 cell invasion was linked to 5-HT7 receptor-dependent Gαs and Gβγ signaling. a The invasivenesses of MDA-MB-231
cells were determined after cells were pretreated with gallein or DDA alone, or a combination of both, for 1 h prior to 5-HT treatment. *P < 0.05 vs.
vehicle-treated controls. #P < 0.05 vs. 5-HT-treated cells. $P < 0.05 vs. 5-HT- and DDA-treated cells. &P < 0.05 vs. 5-HT- and gallein-treated cells. b Cells
were treated with 5-HT or forskolin and cAMP levels were measured. *P < 0.05 vs. vehicle-treated controls. c Protein extracts from MDA-MB-231 cells
treated with 5-HT alone or 5-HT plus gallein were analyzed for the activation of Gβγ-downstream signaling by western blotting. d 5-HT-induced
MDA-MB-231 cell invasion was examined in the presence of various inhibitors, that is, AZM-475271 (AZM), wortmannin (Wort), tricirbine, rapamycin
(Rapa), SB203580, U0126, and PD98059, at the indicated concentrations. *P < 0.05 vs. vehicle-treated controls. #P < 0.05 vs. 5-HT-treated
cells. e Cells were treated with gallein, wortmannin, or DDA, and basal levels of TPH1 and MMP-9 were analyzed by western blotting.
*P < 0.05 vs. vehicle-treated controls
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prior to the experimental endpoint. If a mouse lost 20%
of its body weight due to drug treatment or gained 20%
of body weight due to tumor growth, it was euthanized
early. The study protocol was reviewed and approved be-
forehand by the Institutional Animal Care and Use
Committee of Yeungnam University.
Statistical analysis
Data are presented as means ± SEMs. Statistical signifi-
cance was determined using the Student’s t-test or one-
way Analysis of variance (ANOVA) followed by the
Newman-Keuls comparison method in GraphPad Prism
5.0 software (San Diego, CA, USA). P values of less than
0.05 were considered statistically significant.
Results
The autocrine effect of 5-HT on MDA-MB-231 human
breast cancer cell proliferation was mediated through
5-HT7 receptor
To determine whether 5-HT exerts a mitogenic signal to
TNBCs in an autocrine manner, we first measured the
expression levels of TPH1, the 5-HT synthesizing en-
zyme, in cells. TNBC cells (MDA-MB-231, HCC-1395,
Hs578T) expressed TPH1 higher at the mRNA (Fig. 1a)
and protein levels (Fig. 1b) than hormone-responsive
cells (MCF-7 and T47D). Likewise, 5-HT secretion by
TNBCs, which was measured in Hank's balanced salt so-
lution without serum, was much higher than that se-
creted by hormone-responsive cells or normal breast cell
line (MCF-10A) (Fig. 1c). Knock-down of TPH1 expres-
sion using siRNA significantly reduced the proliferation
of MDA-MB-231 cells (Fig. 1d). Furthermore, exogenous
5-HT application (in the absence of serum) stimulated
MDA-MB-231 cell proliferation, but this mitogenic ac-
tion was not observed in MCF-7 cells (Fig. 1e), possibly
due to differences in 5-HT signaling pathways. To iden-
tify the 5-HT receptors mediating its mitogenic effect,
the proliferation of MDA-MB-231 cells was examined in
the presence of inhibitors of different 5-HT receptors.
The mitogenic effect of 5-HT was blocked by SB269970
(a 5-HT7 antagonist), but not by cyanopindolol (a 5-HT1A
antagonist), LY310762 (a 5-HT1D antagonist), or cinan-
serin (a 5-HT2A/2C antagonist) (Fig. 1f). In addition,
MDA-MB-231 proliferation in the presence of serum was
blocked by SB269970, but not by NAD299 (a 5-HT1A an-
tagonist), SB224289 (a 5-HT1B antagonist), LY310762,
cinanserin, or RS39604 (a 5-HT4 antagonist) (Fig. 1g), sug-
gesting 5-HT7 receptor plays a major role in the mitogenic
Fig. 4 5-HT crosstalks with VEGF by inducing its expression. a VEGF secretions by TNBCs and hormone-responsive breast cancer cells were
measured by ELISA. *P < 0.05 vs. T47D cells. b Cells were treated as described in the legend of Fig. 3c and VEGF protein levels were determined by
western blotting. *P < 0.05 vs. vehicle-treated controls. #P < 0.05 vs. 5-HT-treated cells. c Basal levels of VEGF protein in MDA-MB-231 cells treated with
gallein, wortmannin, or DDA. The bar graphs represent the means ± SEMs of three independent experiments. *P < 0.05 vs. vehicle-treated controls.
d Knockdown of 5-HT7 suppressed VEGF protein expression. *P < 0.05 vs. vehicle- or NT siRNA-treated controls. e Knock-down of TPH1 inhibited VEGF
secretion by MDA-MB-231 cells. *P < 0.05 vs. vehicle- or NT siRNA-transfected controls
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effect of autocrine 5-HT. To further explain the cell-
specific mitogenic action of 5-HT, we examined 5-HT7 re-
ceptor expression in multiple breast cancer cell lines. The
mRNA (Fig. 1h) and protein (Fig. 1i) expression levels of
5-HT7 receptor in TNBCs (including MDA-MB-231 cells)
were much higher than in MCF-7 and T47D cells. In
addition, in MCF-10A normal breast cells which express
high level of 5-HT7 receptor (Fig. 1h and i), 5-HT did not
stimulate the cell proliferation (Fig. 1j). These results indi-
cate that the mitogenic effect of 5-HT is TNBC cell line
specific. We also examined 5-HT7 downstream signaling
involved in 5-HT-induced proliferation in MDA-MB-231
cells. 5-HT-induced proliferation was suppressed by inhib-
itors of Src (AZM-475271), PI3K (wortmannin), and gal-
lein (a Gβγ inhibitor), but not by inhibitors of adenylyl
cyclase (DDA), mTOR (rapamycin), p38 (SB203580), or
MAPKK (U0126) (Fig. 1k).
5-HT stimulated MDA-MB-231 cell invasion via a 5-HT7
receptor-dependent signaling pathway
We examined whether 5-HT promotes tumor progression
by inducing breast cancer cell invasion. 5-HT stimulated
MDA-MB-231 cell invasion in a concentration-dependent
manner at concentrations as low as 1 μM (Fig. 2a). To de-
termine whether 5-HT7 receptor mediates 5-HT-induced
invasion, we examined whether SB269970 (a 5-HT7 recep-
tor antagonist) prevents cancer cell invasion. An inhibitor
of 5-HT1D (LY310762) was included as a negative control
because it has been reported 5-HT1D is highly expressed in
MDA-MB-231 cells [20]. 5-HT-enhanced MDA-MB-231
cell invasion was found to be blocked by SB269970 but not
by LY310762 (Fig. 2b), indicating 5-HT7 receptor plays a
key role in 5-HT-induced invasion. To confirm the role of
5-HT7 receptor in cell invasion, 5-HT7 receptor expression
was knocked-down using siRNA. Silencing of 5-HT7 (but
not of 5-HT1D) receptor (Fig. 2c and d) abrogated 5-HT-
induced MDA-MB-231 cell invasion (Fig. 2e), and this was
accompanied by a decrease in the expression of matrix
metalloproteinase-9 (MMP-9), a positive regulator of can-
cer cell invasion (Fig. 2c and d). Of note, 5-HT7 knock-
down also reduced the expression of TPH1 (Fig. 2c and d).
To estimate the potential contribution of autocrine 5-HT
to cell invasion, we knocked down TPH1 expression using
TPH1 siRNA, and it was found that this inhibited the inva-
sion of MDA-MB-231 cells in the presence of serum
(Fig. 2f), suggesting that the important autocrine function
of 5-HT during MDA-MB-231 cancer cell invasion.
We next investigated signaling molecules downstream
of 5-HT7 receptor involved in cancer cell invasion. First,
to identify G protein component(s) responsible for the
Fig. 5 Inhibitory effects of BJ-1113 on 5-HT-induced invasion and proliferation of MDA-MB-231 cells. a Chemical structure of BJ-1113. b Treatment of
MDA-MB-231 cells and HCC-1395 cells with BJ-1113 concentration-dependently suppressed 5-HT-induced invasion. c Measurements of MDA-MB-231
proliferation in the absence or presence of BJ-1113. d Serum-induced MDA-MB-231 cell proliferation was significantly inhibited by BJ-1113, and this
was greater than the inhibition observed for SB269970. e BJ-1113 suppressed serum-induced proliferation in HCC-1395, TNBC cells but not in MCF-10A
normal breast cells. f Western blot analyses of 5-HT-induced TPH1, MMP-9 and VEGF expressions in BJ-1113-treated MDA-MB-231 cells. *P < 0.05 vs.
vehicle-treated controls. #P < 0.05 vs. 5-HT-treated cells
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effect of 5-HT, invasion assays were performed in the
presence of G protein component-specific inhibitors,
that is, DDA (a Gαs-linked adenylate cyclase inhibitor)
or gallein (a Gβγ inhibitor). 5-HT-stimulated cell inva-
sion was significantly suppressed by DDA and by gallein
(Fig. 3a). In addition, co-treatment with DDA and gallein
completely stopped 5-HT-induced invasion (Fig. 3a),
suggesting that Gαs and Gβγ mediate 5-HT-induced
cancer cell invasion in concert. As was expected from
the involvement of Gαs in 5-HT-induced invasion, intra-
cellular cAMP levels were increased after treating MDA-
MB-231 cells with 5-HT, but notably, this increase in
cAMP was much smaller than that induced by forskolin
(the activator of adenylyl cyclase) (Fig. 3b), suggesting
Gαs of 5-HT7 receptor may not be fully functional at the
basal level. Downstream signaling molecules of Gβγ, that
is, Src, PI3K (p85), Akt, and mTOR, were found to be
activated (phosphorylated) in 5-HT-treated cells, and
these activations were inhibited by gallein (Fig. 3c),
which is consistent with the involvement of Gβγ in 5-
HT-induced cell invasion. To confirm the roles of these
signaling pathways in 5-HT-induced cancer cell invasion,
invasion assays were performed using MDA-MB-231 cells
in the presence of inhibitors of different signaling path-
ways. The 5-HT-induced invasion of MDA-MB-231 can-
cer cells was blocked by inhibitors of Src (AZM-475271),
PI3K (wortmannin), Akt (tricirbine), MAPKK (U0126), or
ERK (PD98059) (Fig. 3d), but interestingly, not by inhibi-
tors of mTOR (rapamycin) or p38 (SB203580) (Fig. 3d),
indicating that not all activated Gβγ signaling molecules
were involved in the 5-HT-induced invasion. To deter-
mine the role of signaling molecules in the altered expres-
sions of downstream genes involved in 5-HT-induced
invasion, we examined the expression levels of MMP-9
and TPH1 in the presence of inhibitors of signaling path-
ways including, Gαs (DDA), Gβγ (gallein), and PI3K
(wortmannin). Basal TPH1 expression was suppressed by
gallein and wortmannin, but not by DDA (Fig. 3e),
whereas all three inhibitors suppressed MMP-9 expression
(Fig. 3e), suggesting that the signaling pathway linked to
MMP-9 expression was different from that required for
TPH1 expression.
5-HT crosstalk with VEGF and the induction of VEGF
expression by 5-HT: Suppression by BJ-1113
Previous studies have suggested potential overlap be-
tween the 5-HT and VEGF signaling pathways [29], both
of which apparently promote cancer cell growth and sur-
vival. To determine whether there indeed is overlap be-
tween these signaling pathways, we examined whether
VEGF expression is altered by 5-HT or inhibitors of
signaling pathways involved in the effects of 5-HT.
VEGF secretion from TNBCs in the absence of serum
was much higher than from hormone-responsive cells
(Fig. 4a), and its expression was increased in the pres-
ence of 5-HT (Fig. 4b). Furthermore, 5-HT-induced
VEGF expression was suppressed in the presence of in-
hibitors of Gβγ and PI3K (Fig. 4c). In addition, knock-
down of 5-HT7 or TPH1 led to significant decreases in
VEGF protein expression (Fig. 4d) and VEGF concentra-
tions in culture media (Fig. 4e), respectively. Together,
these results indicate overlapping between the 5-HT and
VEGF signaling pathways and suggest potential crosstalk
between the two.
To examine the possibility of crosstalk, we next
examined whether BJ-1113 exerts an inhibitory effect on
5-HT-induced TNBC progression. BJ-1113 concentration-
dependently inhibited 5-HT-induced MDA-MB-231 cell
invasion (Fig. 5b) and proliferation (Fig. 5c), and serum-
induced TNBC proliferation was significantly inhibited by
BJ-1113 more so than by SB269970 (Fig. 5d). The inhibi-
tory effects of BJ-1113 on invasion (Fig. 5b) and prolifera-
tion (Fig. 5e) were similarly observed in the other TNBC
cell line, HCC-1395. Similar to 5-HT which had no mito-
genic effect on MCF-10A cells, BJ-1113 did not inhibit
MCF-10A cell proliferation (Fig. 5e). To elucidate the mo-
lecular mechanism involved, the expressions of TPH1,
MMP-9, and VEGF were examined in BJ-1113-treated
MDA-MB-231 cells. Treatment with BJ-1113 significantly
suppressed the 5-HT-enhanced expressions of TPH1,
MMP-9, and VEGF (Fig. 5f), and consequently, the
secretions of VEGF and 5-HT (Table 1), suggesting that
BJ-1113 suppresses cancer progression by inhibiting VEGF
expression and the autocrine function of 5-HT.
To investigate the molecular mechanism and identify the
signaling molecules responsible for the action of BJ-1113,
cAMP levels (indicative of Gαs signaling) were measured.
In MDA-MB-231 cells, BJ-1113 concentration-dependently
suppressed 5-HT-induced cAMP generation (Fig. 6a). We
also noted the possibility that Gαs of 5-HT7 receptor might
not be fully functional at basal level (Fig. 3b). To clarify the
involvement of G protein in determining the action
of BJ-1113, MDA-MB-231 cells were treated with an acti-
vator of Gαs (cholera toxin) or an inhibitor of Gαi (pertus-
sis toxin) and intracellular cAMP levels were measured.
As was expected, cholera toxin increased cAMP levels,
and pertussis toxin enhanced cAMP levels more so than
cholera toxin (Fig. 6b). BJ-1113 consistently suppressed
both cholera toxin- and pertussis toxin-induced cAMP
increases (Fig. 6b), indicating that action site of BJ-1113
Table 1 Secreted levels of 5-HT and VEGF from MDA-MB-231
cells in culture and their inhibition by BJ-1113
VEGF (ng/mg protein) 5-HT (ng/mg protein)
Vehicle 1.9 ± 0.2 28.6 ± 0.4
BJ-1113 (μM) 0.1 1.3 ± 0.1 18.0 ± 0.8
1 1.1 ± 0.2 13.9 ± 0.4
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may be adenylyl cyclase rather than G protein. In terms of
5-HT-activated Gβγ signaling, BJ-1113 significantly inhib-
ited the phosphorylations of PI3K, Akt, and mTOR, but
not of Src, ERK, and p38 (Fig. 6c).
Anti-tumor activities of 5-HT7 receptor antagonist, its
signaling inhibitors, and of BJ-1113 in the MDA-MB-231
xenograft models
MDA-MB-231 cancer cell-inoculated chick chorioallan-
toic membrane (CAM) assay was used to examine the in
vivo efficacies of SB269970 (5-HT7 receptor inhibitor),
wortmannin (an inhibitor of PI3K which is involved in
the signaling of 5-HT7 and VEGF receptors), and BJ-
1113. 5-HT1D receptor antagonist (LY310762) was used
as a negative control. MDA-MB-231 cancer cells inocu-
lated onto CAMs developed into tumor masses that ex-
hibited high degrees of new blood vessel formation, and
this vessel formation was significantly suppressed by
SB269970, wortmannin, and BJ-1113 (Fig. 7a and b). As
was expected based on the anti-invasive and anti-
proliferative effects of BJ-1113 (Fig. 5), BJ-1113 had the
strongest inhibitor effect followed by SB269970 and wort-
mannin (Fig. 7b). To confirm the anticancer activity of BJ-
1113, we also examined its antitumor effects in mice
xenografted with MDA-MB-231-effluc cells and compared
these with those of cisplatin. Because preliminary results
showed cisplatin at 3 mg/kg was highly toxic, we adminis-
tered cisplatin at 1 mg/kg. BJ-1113 dose-dependently sup-
pressed tumor growth (Fig. 7c), although at 1 mg/kg, its
inhibitory effect was slightly less than that of cisplatin. In
vivo optical imaging also revealed that BLI signals emitted
by tumors were much lower in cisplatin- or BJ-1113-
treated mice than in vehicle-treated mice (Fig. 7d). Of
note, in vivo BLI imaging revealed greatest inhibition of
tumor growth in mice treated with 10 mg/kg BJ-1113. On
day 19 after first drug treatment, the effect of BJ-1113 at
10 mg/kg on tumor growth was dramatic, as 53% decrease
in tumor volume and 85% decrease in tumor weight was
observed in the BJ-1113-treated group (mean tumor vol-
ume 240.20 ± 29.53 mm3, tumor weight 171.7 ± 38.7 mg)
as compared with vehicle-treated controls (mean
tumor volume 448.87 ± 20.30 mm3, tumor weight
1146.7 ± 183.05 mg) (Fig. 7c and e). However, the body
weights (a marker of toxicity) of BJ-1113-treated mice
were similar to those of vehicle-treated controls, whereas
cisplatin-treated mice showed progressive body weight
loss (Fig. 7f). In addition, compared to vehicle-treated
control group, TPH1 and VEGF protein expression was
suppressed by BJ-1113 in MDA-MB-231 effluc tumor
(Fig. 7g).
Fig. 6 Inhibitory effect of BJ-1113 on Gαs and Gβγ signaling in MDA-MB-231 breast cancer cells. a, b Inhibitory effects of BJ-1113 on cAMP levels
were investigated using a cAMP ELISA kit. In a, cAMP level was measured in cells treated with 5-HT in the absence or presence of BJ-1113. *P < 0.05 vs.
vehicle-treated controls. #P < 0.05 vs. 5-HT-treated cells. In b, BJ-1113 inhibited cholera toxin- and pertusis toxin-induced cAMP in MDA-MB-231 cells.
*P < 0.05 vs. vehicle-treated controls. #P < 0.05 vs. cholera toxin- or pertusis toxin-treated cells. c Inhibitory effect of BJ-1113 on the activation of
Gβγ-downstream signaling in 5-HT-stimulated MDA-MB-231 cells. The results in bar graphs represent the relative densities of each signaling protein
of phospho-to-parent and are the means ± SEMs of three independent experiments. *P< 0.05 vs. vehicle-treated controls. #P< 0.05 vs. 5-HT-treated cells
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Discussion
The present study shows, for the first time, that auto-
crine 5-HT stimulates TNBC progression. This con-
clusion is based on the observations that; 1) TNBCs
(MDA-MB-231, HCC-1395, and Hs578T) expressed
higher levels of TPH1 and 5-HT7 receptor, and secreted
more 5-HT than hormone-positive cells (MCF-7 and
T47D), 2) silencing of TPH1 or 5-HT7 receptor blocked
cancer invasion and proliferation.
Invasion and proliferation are mutually incompatible
phenotypes and are required for the malignant progres-
sion of cancer, during which proliferation after invasion
supports the malignant process by maintaining cell
numbers. These processes could be achieved if different
sub-clones of phenotypes with proliferative, invasive, or
both phenotypes co-exist in a single tumor [26–28].
Likewise, the present study shows MDA-MB-231 cells in
culture responded to 5-HT stimulation by increasing
their invasive and proliferative abilities, which indicates
MDA-MB-231 cells in culture possessed both prolifera-
tive and invasive phenotypes. In addition, the stimula-
tory effect of 5-HT on MDA-MB-231 cell invasion
(Fig. 2a) was found to be greater than its effect on cell
proliferation (Fig. 1e), which suggests that 5-HT acts
more strongly during the first stage of the metastatic
process, that is by promoting invasion and migration
through extracellular matrix, rather than during the later
proliferative phase after local invasion or migration to
new sites. Of note, we identified the downstream signal-
ing molecules responsible for transmitting signals from
5-HT7 receptor that lead to either TNBC cell prolifera-
tion or invasion.
In a previous study, it was reported MDA-MB-231
cells express 5-HT1D and 5-HT7 receptors [20], but in
the present study only 5-HT7 receptor was found to be
associated with their invasion and proliferation.
Fig. 7 The inhibitory effects of BJ-1113 on xenografted MDA-MB-231 tumor growth on CAM and in nude mice. a, b MDA-MB-231 human breast
cancer cells (2 × 106 cells/CAM) were inoculated on top of CAM; drug were mixed with cell suspension before inoculation. The tumor growth and
angiogenesis shown in a were quantitated and are expressed as the numbers of new vessel branches formed and tumor weights (b). A representative
tumor mass isolated from CAM: 1, vehicle control; 2, LY310762-treated group; 3, SB269970-treated group; 4, wortmannin (Wort) treated group; and 5,
BJ-1113-treated group. *P < 0.05 vs. PBS-treated controls. #P < 0.05 vs. SB269970 or Wort treated cells. c-e. BALB/c nude mice bearing MDA-MB-231-effluc
cells were administered intraperitoneally with cisplatin or BJ-1113 for 19 consecutive days. In each group, six mice were used. c Tumor growth was
monitored by measuring tumor size. d Bioluminescent imaging of tumors was performed as described in Material and Methods; in addition, e tumor
tissues were isolated and their weights were recorded. *P< 0.05 vs. vehicle-treated control mice. #P < 0.05 vs. cisplatin-treated mice. f Unlike cisplatin,
treatment with BJ-1113 for 19 days did not alter body weights. g BJ-1113 inhibited TPH1 and VEGF protein expression in MDA-MB-231 effluc tumor.
*P < 0.05 vs. vehicle-treated control mice
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Silencing and treatment with 5-HT7 receptor inhibitor
suppressed 5-HT-induced breast cancer progression.
Furthermore, increased TPH1 expression was main-
tained by autocrine 5-HT in TNBC cells, which is very
different from MCF-10A normal breast cell line. In
MCF-10A cells which barely produced 5-HT despite
high level expression of 5-HT7 receptors, 5-HT had no
mitogenic effect on the cells, which is consistent to pre-
vious reports [20]. These results suggest that 5-HT sig-
naling via 5-HT7 receptor offers a promising therapeutic
target for TNBC. Consistent with a previous report that
cellular signaling in an invasive subclone of cancer cells
is dependent on mitogen-activated protein kinase (MAPK)
[26], we observed 5-HT-activated ERK was involved in in-
vasion, but not in proliferation. In contrast, PI3K/Akt, the
other downstream signal of 5-HT7 receptor-linked Gβγ
activation, was involved in the invasion and proliferation
of MDA-MB-231 cells. Although PI3K/Akt is also a
downstream signaling molecule of growth factor recep-
tors, PI3K inhibitors that block the signal overlap between
5-HT and growth factors may not be enough to suppress
TNBC progression fully. However, complete blockade of
5-HT-induced MDA-MB-231 cell invasion occurred when
the activities of both Gαs and Gβγ were inhibited by
a 5-HT7 antagonist or by dual inhibition (DDA and gal-
lein). In this study, we suggest BJ-1113 being considered
as a potential anticancer agent that suppresses TNBC
progression, by inhibiting both the Gαs-linked generation
of cAMP and activation of the PI3K/Akt pathway (Fig. 8),
and thus, suppressing invasion and proliferation of MDA-
MB-231 cancer cells stimulated by 5-HT or serum. The
efficacy of BJ-1113 (at 10 μM) at suppressing 5-HT-
induced cancer cell invasion was similar to that achieved
by co-treating DDA (100 μM) and gallein (10 μM), which
hints that BJ-1113 may target the autocrine action of
5-HT by inhibiting Gα and Gβγ signaling. However, be-
cause the inhibitory effect of BJ-1113 on cAMP produc-
tion was not specific to Gs or Gi (Fig. 6b), BJ-1113 may
not act at the 5-HT7 receptor itself. Rather, it inhibits ade-
nylyl cyclase directly (Fig. 8). In addition, BJ-1113 did not
inhibit phosphorylation of Src and ERK, signaling
molecules downstream of Gβγ subunit. Therefore, inhib-
ition of PI3K/Akt phosphorylation by BJ-1113 indicates
that BJ-1113 may directly inhibit PI3K activity. This add-
itional PI3K/Akt inhibitory activity of BJ-1113 could give
rise to a stronger inhibitory effect in tumor growth than
SB269970.
In addition to stimulating 5-HT production, we also
demonstrate for the first time that autocrine 5-HT in
MDA-MB-231 cells also stimulates the induction of
VEGF, a well-known angiogenic factor that is produced
and released by cancer cells. Furthermore, VEGF induc-
tion by 5-HT is mediated by the PI3K/Akt pathway, the
same signaling pathway that increased cell proliferation
Fig. 8 Schematic diagram of 5-HT signaling and of the mode of action of BJ-1113 during breast cancer progression
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in MDA-MB-231 cells and that was blocked by BJ-1113.
Given the strong antiangiogenic activity of BJ-1113
against VEGF [30], the inhibitory effects of BJ-1113 on
the expressions of TPH1 and VEGF in MDA-MB-231
cells indicate BJ-1113 exhibits the properties required of
an anti-cancer agent for tumors resistant to anti-VEGF
therapy. Moreover, considering that cancer is often ac-
companied by thromboembolic complications [36–38],
significant levels of 5-HT released by activated platelets
promote angiogenesis in endothelial cells, and thus,
BJ-1113 could be expected to serve as a multi-faceted
anti-angiogenic anti-cancer agent by acting on cancer
cells and endothelial cells.
In the current study, in vivo anti-cancer activity of
BJ-1113 was evaluated in a subcutaneous (s.c.) xenograft
mouse model. The s.c. xenograft model does not provide
tumor microenvironment interactions that lead to devel-
opment of distant metastasis as in orthotopic xenografts.
However, s.c. xenografts are easy to implant and measure
the tumor size. Although future study evaluating in vivo
efficacy of BJ-1113 in patient-derived tumor xenografts,
which retain genetic characteristics and complex tumor
heterogeneity evident in donor tumor from patients, is re-
quired before moving into clinical trial in drug develop-
ment processes, our results showing strong anti-cancer
activity of BJ-1113 without altering body weight in the s.c
xenograft mouse model of MDA-MB-231 human breast
cancer supports the promising possibility of BJ-1113 as an
anti-cancer therapeutic agent.
Conclusions
In summary, the current study demonstrates for the first
time that autocrine 5-HT acts as a stimulator of breast
cancer progression (Fig. 8). Considering the high ex-
pression of 5-HT and 5-HT7 receptors in TNBC and
5-HT-induced angiogenesis, we believe the suppression
of 5-HT signaling linked to breast cancer progression and
endothelial responses by using BJ-1113 constitutes a novel
approach to cancer therapy against drug-resistant breast
cancer growth and metastasis.
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